At the Virtual Great Debates & Updates in Hematologic Malignancies, Jonathon Cohen, MD, presented standard treatment regiments and novel agents for the treatment of MCL.
Among patients with NSCLC, first-line nivolumab plus ipilimumab combined with chemo yields greater OS than chemo alone.
From March 1-5, cancer care professionals from a variety of specialties and care delivery settings will convene virtually for the ACCC 47th Annual Meeting & Cancer Center Business Summit.
The FDA has approved cemiplimab-rwlc for the first-line treatment of patients with advanced NSCLC with high PD-L1 expression and no EGFR, ALK, or ROS1 aberrations.
Data from a community-based cohort study of patients with NMIBC suggest that 1- and 5-year high-risk recurrences and progression increase with higher tumor classification and grade at diagnosis.
The FDA has approved cemiplimab-rwlc, a PD-1 blocking antibody, for the treatment of patients with locally advanced basal cell carcinoma (laBCC) and has metastatic BCC (mBCC).
The FDA has approved lisocabtagene maraleucel, a new CAR-T therapy, for the treatment of adults with relapsed or refractory large B-cell lymphoma after at least 2 lines of systemic therapy.
Prolonged adjuvant imatinib for high-risk GIST led to a superior OS over shorter-term imatinib treatment, according to a trial comparing 3- and 1-year regimens.
The FDA granted accelerated approval to umbralisib for the treatment of adults with relapsed/refractory FL or MZL.
Certain treatment options when added to androgen-deprivation therapy (ADT) have improved overall survival (OS) among those with metastatic castration-sensitive prostate cancer (mCSPC).
Stay in the know.
OncNet Newsletter